The Pharmacy Times® Oncology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.
What can we help you find?
Review of the pharmacist’s role in outpatient care for acute myeloid leukemia.
The cause of the majority of rare diseases is associated with 80% of the cases being genetically linked due to inheritance of mutated genes.
Over time, hub operations have matured to act as sort of a middleman between manufacturers and specialty pharmacies.
Description of the traditional inpatient administrations versus outpatient treatment processes in acute myeloid leukemia.
According to study findings published in Cancer, mammography screenings reduce the rates of advanced and fatal cancers by more than 40%.
Many pharmaceutical manufacturers consider accreditation a prerequisite when either building their network or adding pharmacies to their network.
New treatments with biological agents and vaccines are creating a pathway for patients with metastatic CRC.
The approval is based on an interim analysis from the phase 3 IMpower110 study, which showed atezolizumab monotherapy improved overall survival by 7.1 months compared with chemotherapy in people with high PD-L1 expression, according to a press release.
The anti-cancer medicine venetoclax may improve the current therapy for estrogen receptor-positive (ER+) breast cancer.
Ripretinib is indicated for adult patients who have received prior treatment with 3 or more kinase inhibitor therapies, including imatinib, according to an FDA press release.
Experts discuss the identification and Medical Utilization Evaluation of patients with newly diagnosed acute myeloid leukemia.
Study Finds High Adherence Rates, Low Adverse Effects Among Breast Cancer Patients Taking CDK 4/6 Inhibitors
Although the average wholesale price of the agents is more than $13,000, the investigators found that 9% of patients had a 0% co-pay throughout the 6-month period.